189 related articles for article (PubMed ID: 35158055)
1. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease.
Zou B; Odden MC; Nguyen MH
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):435-444.e6. PubMed ID: 35158055
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
Pinyopornpanish K; Al-Yaman W; Butler RS; Carey W; McCullough A; Romero-Marrero C
Am J Gastroenterol; 2021 Nov; 116(11):2258-2269. PubMed ID: 34212895
[TBL] [Abstract][Full Text] [Related]
3. Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Case-control Study.
German MN; Lutz MK; Pickhardt PJ; Bruce RJ; Said A
J Clin Gastroenterol; 2020 Sep; 54(8):733-740. PubMed ID: 31567625
[TBL] [Abstract][Full Text] [Related]
4. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
[TBL] [Abstract][Full Text] [Related]
5. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
[TBL] [Abstract][Full Text] [Related]
6. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.
Simon TG; Duberg AS; Aleman S; Hagstrom H; Nguyen LH; Khalili H; Chung RT; Ludvigsson JF
Ann Intern Med; 2019 Sep; 171(5):318-327. PubMed ID: 31426090
[TBL] [Abstract][Full Text] [Related]
7. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.
Kim GA; Park Y; Oh SJ; Jung J; Han S; Chang HS; Park SW; Kim TH; Park HW; Choe J; Kim J; Lee HC
Liver Int; 2024 Mar; 44(3):738-748. PubMed ID: 38110797
[TBL] [Abstract][Full Text] [Related]
8. Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Zhang J; Fu S; Liu D; Wang Y; Tan Y
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):353-358. PubMed ID: 36719824
[TBL] [Abstract][Full Text] [Related]
9. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
Kramer JR; Natarajan Y; Dai J; Yu X; Li L; El-Serag HB; Kanwal F
Hepatology; 2022 Jun; 75(6):1420-1428. PubMed ID: 34779535
[TBL] [Abstract][Full Text] [Related]
10. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Goh MJ; Sinn DH; Kim S; Woo SY; Cho H; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Hepatology; 2020 Jun; 71(6):2023-2032. PubMed ID: 31556128
[TBL] [Abstract][Full Text] [Related]
11. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
Chen J; Song S; Li X; Bian D; Wu X
Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
[TBL] [Abstract][Full Text] [Related]
13. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
14. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC).
Chu J; Cholankeril G; Yu X; Rana A; Natarajan Y; El-Serag HB; Kramer J; Kanwal F
Dig Dis Sci; 2023 Mar; 68(3):1060-1070. PubMed ID: 35759159
[TBL] [Abstract][Full Text] [Related]
15. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis.
Kim HW; Joo YS; Kang SC; Koh HB; Han SH; Yoo TH; Kang SW; Park JT
Sci Rep; 2022 Jun; 12(1):10807. PubMed ID: 35752695
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma and non-alcoholic fatty liver disease.
Golabi P; Rhea L; Henry L; Younossi ZM
Hepatol Int; 2019 Nov; 13(6):688-694. PubMed ID: 31701393
[TBL] [Abstract][Full Text] [Related]
19. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.
Kawamura Y; Arase Y; Ikeda K; Seko Y; Imai N; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ohmoto Y; Amakawa K; Tsuji H; Kumada H
Am J Gastroenterol; 2012 Feb; 107(2):253-61. PubMed ID: 22008893
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
Noureddin M; Rinella ME
Clin Liver Dis; 2015 May; 19(2):361-79. PubMed ID: 25921668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
